CLOSED STUDIES / Ovarian Cancer


GEICO 0104


Title

Phase II randomized study of the carboplatin-gemcitabine doublet followed by carboplatin-paclitaxel versus carboplatin-paclitaxel in platinum-sensitive relapse patients with ovarian carcinoma, primary peritoneal carcinomatosis or fallopian tube carcinoma.


GEICO Coordinator

Dr. Antonio González


Patients Recruited

98 patients


Inclusion Closing Date

June of 2007


Publication

ESMO Poster Nº: 980 – RANDOMIZED PHASE II STUDY OF PACLITAXELCARBOPLATIN (PC) VERSUS GEMCITABINE-CARBOPLATIN (GC) FOLLOWED BY PACLITAXEL-CARBOPLATIN (PC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (PSROC): A GEICO (SPANISH GROUP FOR INVESTIGATION IN OVARIAN CANCER) STUDY A. Gonzalez Martin, A. Casado, J. Arranz, M.J. Rubio, E. Calvo, M. Beltran, C. Mendiola, A. Sanchez, A. Santaballa, A. Cervantes.